Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 39 Leukemia, Myeloid, Acute 35 Myelodysplastic Syndromes 33 Multiple Myeloma 30 Lymphoma, Non-Hodgkin 29 Hodgkin Disease 28 Graft vs Host Disease 26 Leukemia, Lymphocytic, Chronic, B-Cell 25 Lymphoma 24 Leukemia 24 Hematologic Neoplasms 20 Neoplasms 18 Lymphoma, Mantle-Cell 18 Sarcoma 17 Leukemia, Myelogenous, Chronic, BCR-ABL Positive 17 Breast Neoplasms 17 Tuberous Sclerosis 15 Myeloproliferative Disorders 15 Lymphoma, Large B-Cell, Diffuse 15 Lymphoma, Follicular 14 Burkitt Lymphoma 14 Waldenstrom Macroglobulinemia 13 Lymphoma, B-Cell, Marginal Zone 13 Recurrence 12 Neoplasm Metastasis 12 Carcinoma, Non-Small-Cell Lung 12 Prostatic Neoplasms 11 Primary Myelofibrosis 11 Melanoma 11 Leukemia, Myelomonocytic, Chronic 11

Interventions

cemiplimab 3 Transdermal Patch 1 Sirolimus 1 Prednisone 1 Everolimus 1 Doxorubicin 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Cutaneous Squamous Cell Carcinoma × Sirolimus × Clear all

NCT04339062 2025-04-23

CONTRAC

Dana-Farber Cancer Institute

Phase 1/2 Completed

12 enrolled 13 charts

Cutaneous Squamous Cell Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡